147 related articles for article (PubMed ID: 38281053)
1. A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial.
Li J; Xu C; Yuan S
Cost Eff Resour Alloc; 2024 Jan; 22(1):8. PubMed ID: 38281053
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
Liu S; Jiang N; Dou L; Li S
Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Lin YT; Zhou CC; Xu K; Zhang MD; Li X
Ther Adv Med Oncol; 2023; 15():17588359231213621. PubMed ID: 38028139
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma.
Zheng H; Li J; Wen F; Su N
Front Oncol; 2023; 13():1216960. PubMed ID: 38023250
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China.
Chen F; Long Y; Yang J; Zhong K; Liu B
BMJ Open; 2023 Dec; 13(12):e078924. PubMed ID: 38149425
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
[TBL] [Abstract][Full Text] [Related]
7. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis.
Zhu Y; Liu K; Qin Q; Zhu H
Front Immunol; 2022; 13():1044678. PubMed ID: 36685541
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More.
Zheng Z; Lin J; Zhu H; Cai H
Front Public Health; 2022; 10():893387. PubMed ID: 35774581
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer.
Zheng Z; Chen H; Cai H
Front Oncol; 2023; 13():1259574. PubMed ID: 38282674
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma.
Zheng Z; Fang L; Cai H; Zhu H
Immunotherapy; 2023 Sep; 15(13):1045-1055. PubMed ID: 37401267
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China.
Xiang G; Jiang T; Gan L; Wu Y; Zhang N; Xing H; Su H; Li Y; Peng D; Ni R; Liu Y
Front Immunol; 2023; 14():1223020. PubMed ID: 37720211
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients.
Zheng H; Zeng Y; Wen F; Hu M
Front Immunol; 2024; 15():1382088. PubMed ID: 38711525
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China.
Ma Y; Zhou J; Ye Y; Wang X; Ma A; Li H
Front Oncol; 2023; 13():1113346. PubMed ID: 37182176
[TBL] [Abstract][Full Text] [Related]
14. Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.
Shao T; Zhao M; Liang L; Tang W
BioDrugs; 2023 May; 37(3):421-432. PubMed ID: 36840914
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States.
Hu J; Ye Z; Xu Z; Hao Z; Wang Y
Front Public Health; 2022; 10():941738. PubMed ID: 36568792
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
Zhan M; Xu T; Zheng H; He Z
Front Public Health; 2022; 10():790225. PubMed ID: 35309225
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma.
Liu S; Dou L; Wang K; Shi Z; Wang R; Zhu X; Song Z; Li S
Front Oncol; 2022; 12():899966. PubMed ID: 35936686
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China.
Long Y; Xu Y; Liao L; Zhou Y; Wang H
BMJ Open; 2023 Aug; 13(8):e072106. PubMed ID: 37586861
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China.
Kang S; Liu H
Expert Rev Pharmacoecon Outcomes Res; 2023 Nov; ():1-8. PubMed ID: 37936507
[TBL] [Abstract][Full Text] [Related]
20. First-line nivolumab plus ipilimumab or chemotherapy
Cao X; Cai H; Li N; Zheng B; Zheng Z; Liu M
Ther Adv Med Oncol; 2022; 14():17588359221122733. PubMed ID: 36147862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
